Aktis Oncology to Present at the BofA Securities Health Care Conference

Aktis Oncology (NASDAQ:AKTS) will present at the BofA Securities Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 10:00 a.m. PT.

Rhea-AI Summary

Aktis Oncology (NASDAQ:AKTS) will present at the BofA Securities Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 10:00 a.m. PT.

Matthew Roden, Ph.D., President and CEO, will deliver the presentation. A live webcast and an archived replay (available ~90 days) will be accessible via the Investors section of the Aktis website.

Argus May 6 session

+3.03% close to close Open Argus

Details

News Market Reaction – AKTS

On May 6, the day this news came out, AKTS closed 3.03% above the previous close.

Data tracked by StockTitan Argus for the May 6 session.

Market Context

This announcement highlights an investor-focused catalyst: a BofA health care conference presentatio...

Analysis

This announcement highlights an investor-focused catalyst: a BofA health care conference presentation on May 13, 2026, with a webcast and a 90-day replay. Set against recent FDA clearances, clinical updates, and substantial financing milestones, the conference primarily enhances visibility rather than altering fundamentals. Investors tracking the story may focus on how management frames progress on AKY-1189, AKY-2519, and the broader radiopharmaceutical platform in this forum.

Key Figures

Conference date: May 13, 2026 Presentation time: 10:00 a.m. PT Replay availability: 90 days

Conference date

May 13, 2026

BofA Securities Health Care Conference presentation date

Presentation time

10:00 a.m. PT

Scheduled time for BofA conference presentation

Replay availability

90 days

Archived webcast available after the conference

Historical Context

5 past events · Latest: May 03

5 events

1. May 03

   Peer M&A mention

   24h Move

   -2.2%

   Third-party acquisition where Aktis is cited for its IPO track record.

2. Apr 21

   Clinical data update

   24h Move

   +6.8%

   Announcement of first clinical imaging and dosimetry data for AKY-2519 at ASCO.

3. Apr 16

   Board appointment

   24h Move

   +2.8%

   Appointment of experienced R&D leader Glenn Gormley and creation of science committee.

4. Mar 30

   FDA and earnings

   24h Move

   +8.2%

   FDA IND clearances, full-year 2025 results, and detailed pipeline and cash updates.

5. Feb 24

   Investor conferences

   24h Move

   -2.5%

   CEO presentations at two March investor conferences with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

targeted radiopharmaceuticals

1 terms

targeted radiopharmaceuticals medical

"a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals"

Targeted radiopharmaceuticals are medicines that combine a small amount of radioactive material with a molecule that seeks out particular cells or proteins, acting like a guided missile that delivers radiation directly to diseased tissue such as a tumor. For investors they matter because they can offer highly focused treatments with potentially large clinical benefit, but they also involve complex development, strict regulation, manufacturing challenges and specific reimbursement questions that affect commercial value and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the BofA Securities Health Care Conference in Las Vegas, Nevada. The presentation will take place on Wednesday, May 13, 2026, at 10:00 a.m. PT.

A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.

About Aktis’ miniprotein radioconjugate platform
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most advanced clinical-stage pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second clinical-stage pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung, colorectal, and other solid tumors. Aktis has a discovery collaboration with Eli Lilly and Company to leverage Aktis’ miniprotein platform to develop novel radioconjugates outside of its proprietary pipeline. For more information, please visit www.aktisoncology.com.

Media contact:
Melone Communications, LLC
Liz Melone
617-256-6622
liz@melonecomm.com

Investor contact:
Precision AQ
Alex Lobo
212-698-8802
Alex.lobo@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Aktis Oncology (AKTS) present at the BofA Securities Health Care Conference?

Aktis Oncology will present on Wednesday, May 13, 2026 at 10:00 a.m. PT. According to Aktis Oncology, Matthew Roden, Ph.D., President and CEO, will deliver the presentation at the Las Vegas conference.

How can investors watch the AKTS presentation at the BofA conference?

Investors can watch a live webcast via the Aktis website Investors section at investors.aktisoncology.com. According to Aktis Oncology, an archived replay will be available on the site for approximately 90 days after the event.

Who from Aktis Oncology (AKTS) will present at the BofA Securities Health Care Conference?

Matthew Roden, Ph.D., President and Chief Executive Officer, will present on behalf of Aktis Oncology. According to Aktis Oncology, he will speak at the May 13, 2026 session in Las Vegas at 10:00 a.m. PT.

Will there be an archived replay of the AKTS BofA conference presentation?

Yes. An archived replay will be available on the Aktis website for about 90 days following the conference. According to Aktis Oncology, the replay will be posted in the Investors section after the live webcast.

What topics might Aktis Oncology (AKTS) cover during the May 13, 2026 presentation?

The presentation will likely focus on Aktis Oncology's clinical-stage targeted radiopharmaceutical programs and corporate update. According to Aktis Oncology, the company is focused on expanding targeted radiopharmaceuticals to broader patient populations.